Literature DB >> 9160035

Ocular ischemic syndrome.

J B Mizener1, P Podhajsky, S S Hayreh.   

Abstract

PURPOSE: The purpose of the study is to investigate the clinical features and management of ocular ischemic syndrome (OIS) and factors influencing its development. INTERVENTION: The following interventions were used: detailed medical and ocular histories, complete ophthalmic evaluation including fluorescein angiography, internal carotid artery evaluation by duplex ultrasonography, and/or aortic arch angiography, management, and follow-up. MAIN OUTCOME MEASURES: The following outcome measures were considered: visual acuity, visual fields, intraocular pressure, anterior segment neovascularization and other abnormalities, lens, optic disc, retinal and choroidal changes, carotid artery stenosis or occlusion, diabetes mellitus, arterial hypertension, coronary artery disease, and cerebrovascular disease.
RESULTS: Mean age of the 32 patients (39 eyes) with OIS was 68 +/- 8 years. Presenting visual symptoms included amaurosis fugax (15%) and/or gradual (28%) or sudden (41%) visual loss. At initial visit, eyes with OIS had visual acuity less than or equal to 20/400 in 64%, iris neovascularization (NV) in 87%, angle NV in 59%, intraocular pressure from 4 to 60 mmHg (median 18 mmHg), optic disc pale (40%) and/or cupped (19%) or edematous (8%), disc NV (13%), retinal NV (3%), marked retinal circulatory stasis (21%), and retinal hemorrhages (24%). Associated systemic diseases in these patients included diabetes mellitus (56%), arterial hypertension (50%), coronary artery disease (38%), and previous stroke or transient ischemic attack (31%); the incidence of diabetes, coronary artery disease, and cerebrovascular disease was much higher in patients with OIS than in the comparable general population, especially that of diabetes. Occlusion or severe stenosis (80%-99%) of the internal carotid artery was seen in 74% on the side of OIS.
CONCLUSIONS: Ocular ischemic syndrome has a poor visual prognosis. However, the ophthalmologist's diagnosis may be crucial to the health of these patients, because OIS may be the presenting sign of serious cerebrovascular and ischemic heart diseases.

Entities:  

Mesh:

Year:  1997        PMID: 9160035     DOI: 10.1016/s0161-6420(97)30221-8

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  50 in total

Review 1.  Management of ocular ischaemic syndrome.

Authors:  R Malhotra; K Gregory-Evans
Journal:  Br J Ophthalmol       Date:  2000-12       Impact factor: 4.638

2.  Resolution of proliferative venous stasis retinopathy after carotid endarterectomy.

Authors:  Christina A Rennie; Declan W Flanagan
Journal:  Br J Ophthalmol       Date:  2002-01       Impact factor: 4.638

3.  Bilateral hypoperfusion retinopathy.

Authors:  A H Dahlmann; D McCormack; R J Harrison
Journal:  J R Soc Med       Date:  2001-06       Impact factor: 5.344

4.  Ocular ischaemic syndrome in thyroid eye disease, confirmed using magnetic resonance angiography.

Authors:  A J Shortt; T Fulcher; D Conroy
Journal:  Br J Ophthalmol       Date:  2003-10       Impact factor: 4.638

Review 5.  Neovascular glaucoma.

Authors:  Sohan Singh Hayreh
Journal:  Prog Retin Eye Res       Date:  2007-08-08       Impact factor: 21.198

6.  Eye syndromes and the neuro-ophthalmology of stroke.

Authors:  Valérie Biousse; Nancy J Newman
Journal:  Handb Clin Neurol       Date:  2009

Review 7.  Ocular vascular occlusive disorders: natural history of visual outcome.

Authors:  Sohan Singh Hayreh
Journal:  Prog Retin Eye Res       Date:  2014-04-21       Impact factor: 21.198

8.  Ocular ischemic syndrome.

Authors:  Jia-Horung Hung; Yi-Sheng Chang
Journal:  CMAJ       Date:  2017-06-12       Impact factor: 8.262

9.  Unilateral visual impairment and health related quality of life: the Blue Mountains Eye Study.

Authors:  E-M Chia; P Mitchell; E Rochtchina; S Foran; J J Wang
Journal:  Br J Ophthalmol       Date:  2003-04       Impact factor: 4.638

10.  Transient Vision Loss.

Authors:  Carolyn Glazer-Hockstein; Nicholas J. Volpe
Journal:  Curr Treat Options Neurol       Date:  2004-01       Impact factor: 3.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.